Cytokines and the Pathophysiology of Skeletal Muscle Atrophy

Pharmacotherapy of Cachexia

Volumn , Issue , 2005, Pages 101-114

  Baracos, Vickie E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971214058     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (76)

1. Baracos V.E., Rodemann H.P., Dinarello C.A., and Goldberg A.L. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N. Engl. J. Med. 1983; 308: 553-8.
2. Kwakk S., Zhou X., Solomon V., Baracos V.E., Davis J., Bannon A.W., Boyle W.J., Lacey D.L., and Han H.Q. Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3a-II during cancer cachexia. Cancer Res. 2004; 64: 8193-8.
3. Acharyya S., Ladner K.J., Nelsen L.L., Damrauer J., Reiser P.J., Swoap S., and Gut-tridge D.C. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 2004; 114: 370-8
4. Spate U. and Schulze P.C. Proinflammatory cytokines and skeletal muscle. Curr. Opin. Clin. Nutr. Metab. Care 2004; 7: 265-9.
5. Langen R.C., Van Der Velden J.L., Schols A.M., Kelders M.C., Wouters E.F., and Janssen-Heininger Y.M. Tumor necrosis factor a inhibits myogenic differentiation through MyoD protein destabilization. FASEB J. 2004; 18: 227-37.
6. Raj D.S., Shah H., Shah V.O., Ferrando A., Bankhurst A., Wolfe R., and Zager P.G. Markers of inflammation, proteolysis, and apoptosis in ESRD. Am. J. Kidney Dis.2003; 42: 1212-20.
7. Pattison J.S., Folk L.C., Madsen R.W., Childs T.E., and Booth F.W. Transcriptional profiling identifies extensive downregulation of extracellular matrix gene expression in sarcopenic rat soleus muscle. Physiol. Genomics. 2003; 15: 34-43.
8. Welle S., Brooks A.I., Delehanty J.M., Needler N., and Thornton C.A. Gene expression profile of aging in human muscle. Physiol. Genomics 2003; 14: 149-59.
9. Li Y.P., Lecker S.H., Chen Y., Waddell I.D., Goldberg A.L., and Reid M.B. TNF-a increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J. 2003; 17: 1048-57.
10. Lang C.H., Hong-Brown L., and Frost R.A. Cytokine inhibition of JAK-STAT signaling: a new mechanism of growth hormone resistance. Pediatr. Nephrol. 2005; 20: 306-12.
11. Frost R.A. and Lang C.H. Alteration of somatotropic function by proinflammatory cytokines. J. Anim. Sci. 2004; 82: E100-9.
12. Strle K., Broussard S.R., McCusker R.H., Shen W.H., Johnson R.W., Freund G.G., Dantzer R., and Kelley K.W. Proinflammatory cytokine impairment of insulin-like growth factor I-induced protein synthesis in skeletal muscle myoblasts requires ceramide. Endocrinology 2004; 145: 4592-602.
13. Tuomisto T.T., Rissanen T.T., Vajanto I., Korkeela A., Rutanen J., and Yla-Herttuala S. HIF-VEGF-VEGFR-2, TNF-a and IGF pathways are upregu-lated in critical human skeletal muscle ischemia as studied with DNA array. Atherosclerosis 2004; 174: 111-20.
14. Foulstone E.J., Huser C., Crown A.L., Holly J.M., and Stewart C.E. Differential signalling mechanisms predisposing primary human skeletal muscle cells to altered proliferation and differentiation: roles of IGF-1 and TNF-a. Exp. Cell. Res. 2004; 294: 223-35.
15. Schulze P.C., Gielen S., Adams V., Linke A., Mobius-Winkler S., Erbs S., Kratzsch J., Hambrecht R., and Schuler G. Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulin like growth factor-I in chronic heart failure. Basic Res. Cardiol. 2003; 98: 267-74.
16. Broussard S.R., McCusker R.H., Novakofski J.E., Strle K., Shen W.H., Johnson R.W., Freund G.G., Dantzer R., and Kelley K.W. Cytokine-hormone interactions: tumor necrosis factor a impairs biologic activity and downstream activation signals of the insulin-like growth factor I receptor in myoblasts. Endocrinology 2003; 144: 2988-96.
17. Frost R.A., Nystrom GJ., and Lang C.H. Tumor necrosis factor-a decreases insulinlike growth factor-I messenger ribonucleic acid expression in C2C12 myoblasts via a Jun N-terminal kinase pathway. Endocrinology 2003; 144: 1770-9.
18. Torres S.H., De Sanctis J.B., de L Briceno M., Hernandez N., and Finol H.J. Inflammation and nitric oxide production in skeletal muscle of type 2 diabetic patients. J. Endocrinol. 2004; 181: 419-27.
19. Carey A.L. and Febbraio M.A. Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia 2004; 47: 1135-42.
20. Bruce C.R. and Dyck D.J. Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-a. Am. J. Physiol. Endocrinol. Metab. 2004; 287: E616-21.
21. Di Rocco P., Manco M., Rosa G., Greco A.V., and Mingrone G. Lowered tumor necrosis factor receptors, but not increased insulin sensitivity, with infliximab. Obes. Res. 2004; 12: 734-9.
22. Kim H.J., Higashimori T., Park S.Y., Choi H., Dong J., Kim Y.J., Noh H.L., Cho Y.R., Cline G., Kim Y.B., and Kim J.K. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004; 53: 1060-7.
23. de Alvaro C., Teruel T., Hernandez R., and Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kB kinase in ap38 MAPK-dependent manner. J. Biol. Chem. 2004; 279: 17070-8.
24. Yamaguchi K., Higashiura K., Ura N., Murakami H., Hyakukoku M., Furuhashi M., and Shimamoto K. The effect of tumor necrosis factor-a on tissue specificity and selectivity to insulin signaling. Hypertens. Res. 2003; 26: 389-96.
25. Beutler B. and Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986; 320: 584-8.
26. Lappas M., Yee K., Permezel M., and Rice G.E. Sulphasalazine and BAY 11-7082 interfere with the NF-kB and IKK^ pathway to regulate the release of pro-inflammatory cytokines from human adipose tissue and skeletal muscle, in vitro. Endocrinology 2005; 146: 1491-7.
27. Hamada K., Vannier E., Sacheck J.M., Witsell A.L., and Roubenoff R. Senescence of human skeletal muscle impairs the local inflammatory cytokine response to acute eccentric exercise. FASEB J. 2005; 19: 264-6.
28. Haddad F., Zaldivar F.P., Cooper D.M., and Adams G.R. IL-6 induced skeletal muscle atrophy. J. Appl. Physiol. 2005; 98: 911-7.
29. Keller C., Keller P., Giralt M., Hidalgo J., and Pedersen B.K. Exercise normalises overexpression of TNF-a in knockout mice. Biochem. Biophys. Res. Commun.2004; 321: 179-82
30. Dennis R.A., Trappe T.A., Simpson P., Carroll C., Huang B.E., Nagarajan R., Bearden E., Gurley C., Duff G.W., Evans W.J., Kornman K., and Peterson C.A. Interleukin-1 polymorphisms are associated with the inflammatory response in human muscle to acute resistance exercise. J. Physiol. 2004; 560: 617-26.
31. Rieusset J., Bouzakri K., Chevillotte E., Ricard N., Jacquet D., Bastard J.P., Laville M., and Vidal H. Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 2004; 53: 2232-41.
32. Tomas E., Kelly M., Xiang X., Tsao T.S., Keller C., Keller P., Luo Z., Lodish H., Saha A.K., Unger R., and Ruderman N.B. Metabolic and hormonal interactions between muscle and adipose tissue. Proc. Nutr. Soc. 2004; 63: 381-5.
33. Zaki M.H., Nemeth J.A., and Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int. J. Cancer 2004; 111: 592-5.
34. Febbraio M.A., Hiscock N., Sacchetti M., Fischer C.P., and Pedersen B.K. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 2004; 53: 1643-8.
35. Kelly M., Keller C., Avilucea P.R., Keller P., Luo Z., Xiang X., Giralt M., Hidalgo J., Saha A.K., Pedersen B.K., and Ruderman N.B. AMPK activity is diminished in tissues of Il-6 knockout mice: the effect of exercise. Biochem. Biophys. Res. Commun.2004; 320: 449-54.
36. Hacham M., White R.M., Argov S., Segal S., and Apte R.N. Interleukin-6 and interleukin-10 are expressed in organs of normal young and old mice. Eur. Cytokine. Netw. 2004, 15: 37-46.
37. Zhang Y., Pilon G., Marette A., and Baracos V.E. Cytokines and endotoxin induce cytokine receptors in skeletal muscle. Am. J. Phys. 2000; 279: E196-205
38. Gallardo E., de Andres I., and Illa I. Cathepsins are upregulated by IFN-y /STAT1 in human muscle culture: a possible active factor in dermatomyositis. J. Neuropathol. Exp. Neurol. 2001; 60: 847-55.
39. Bedard S., Marcotte B., and Marette A. Cytokines modulate glucose transport in skeletal muscle by inducing the expression of inducible nitric oxide synthase. Biochem. J. 1997; 325: 487-93
40. Delaigle A.M., Jonas J.C., Bauche I.B., Cornu O., and Brichard S.M. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology 2004; 145: 5589-97.
41. Carballo-Jane E., Pandit S., Santoro J.C., Freund C., Luell S., Harris G., Forrest M.J., and Sitlani A. Skeletal muscle: a dual system to measure glucocorticoid-dependent transactivation and transrepression of gene regulation. J. Steroid Biochem. Mol. Biol. 2004; 88: 191-201.
42. Baeza-Raja B. and Munoz-Canoves P. p38 MAPK-induced nuclear factor-KB activity is required for skeletal muscle differentiation: role of interleukin-6. Mol. Biol. Cell. 2004; 15: 2013-26.
43. Frost R.A., Nystrom G.J., and Lang C.H. Epinephrine stimulates Il-6 expression in skeletal muscle and C2C12 myoblasts: role of c-Jun N.H.2-terminal kinase and his-tone deacetylase activity. Am. J. Physiol. Endocrinol Metab. 2004; 286: E809-17. [Epub 2004 Jan. 13.]
44. Frost R.A., Nystrom G.J., and Lang C.H. Lipopolysaccharide and proinflammatory cytokines stimulate interleukin-6 expression in C2C12 myoblasts: role of the Jun NH2-terminal kinase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003; 285: R1153-[64].
45. Luo G., Hershko D.D., Robb B.W., Wray C.J., and Hasselgren P.O. Il-1ß stimulates Il-6 production in cultured skeletal muscle cells through activation of MAP kinase signaling pathway and NF-kB. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003; 284: R1249-54.
46. Summan M., McKinstry M, Warren G.L., Hulderman T., Mishra D., Brumbaugh K., Luster M.I., and Simeonova P.P. Inflammatory mediators and skeletal muscle injury: a DNA microarray analysis. J. Interferon Cytokine Res. 2003; 23: 237-45.
47. Ruel M., Bianchi C., Khan T.A., Xu S., Liddicoat J.R., Voisine P., Araujo E., Lyon H., Kohane I.S., Libermann T.A., and Sellke F.W. Gene expression profile after cardiopulmonary bypass and cardioplegic arrest. J. Thorac. Cardiovasc. Surg.2003; 126: 1521-30.
48. Tsivitse S.K., Mylona E., Peterson J.M., Gunning W.T., and Pizza F.X. Mechanical loading and injury induce human myotubes to release neutrophil chemoattractants. Am. J. Physiol. Cell Physiol. 2005; 288: C721-9.
49. Lang C.H., Silvis C., Deshpande N., Nystrom G., and Frost R.A. Endotoxin stimulates in vivo expression of inflammatory cytokines tumor necrosis factor a, interleukin-1, -6, and high-mobility-group protein-1 in skeletal muscle. Shock2003; 19: 538-46.
50. Frost R.A. and Lang C.H. Skeletal muscle cytokines: regulation by pathogen associated molecules and catabolic hormones. Curr. Opin. Clin. Nutr. Metab. Care2005; 8: 255-63.
51. Iwasaki A. and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5: 987-95
52. CookD.N., Pisetsky D.S., and Schwartz D.A. Toll-like receptors in the pathogenesis of human disease. Nat. Immunol. 2004, 5: 975-9.
53. Adembri C., Kastamoniti E., Bertolozzi L., Vanni S., Dorigo W., Coppo M., Pratesi C., De Gaudio A.R., Gensini G.F., and Modesti P.A. Pulmonary injury follows systemic inflammatory reaction in infrarenal aortic surgery. Crit. Care Med. 2004; 32: 1170-7.
54. Chan M.H., Carey A.L., Watt M.J., and Febbraio M.A. Cytokine gene expression in human skeletal muscle during concentric contraction: evidence that Il-8, like Il-6, is influenced by glycogen availability. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004; 287: R322-7.
55. Hiscock N., Chan M.H., Bisucci T., Darby I.A., and Febbraio M.A. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J. 2004; 18: 992-4.
56. Krankel N., Adams V., Gielen S., Linke A., Erbs S., Schuler G., and Hambrecht R. Differential gene expression in skeletal muscle after induction of heart failure: impact of cytokines on protein phosphatase 2A expression. Mol. Genet. Metab.2003; 80: 262-71.
57. Krogh-Madsen R., Plomgaard P., Keller P., Keller C., and Pedersen B.K. Insulin stimulates interleukin-6 and tumor necrosis factor-a gene expression in human subcutaneous adipose tissue. Am. J. Physiol. Endocrinol. Metab. 2004; 286: E234-8.
58. Keller P., Keller C., Carey A.L., Jauffred S., Fischer C.P., Steensberg A., and Pedersen B.K. Interleukin-6 production by contracting human skeletal muscle: autocrine regulation by IL-6. Biochem. Biophys. Res. Commun. 2003; 310: 550-4.
59. Penkowa M., Keller C., Keller P., Jauffred S., and Pedersen B.K. Immunohis-tochemical detection of interleukin-6 in human skeletal muscle fibers following exercise. FASEB J. 2003; 17: 2166-8.
60. Pedersen B.K., Steensberg A., Keller P., Keller C., Fischer C., Hiscock N., van Hall G., Plomgaard P., and Febbraio M.A. Muscle-derived interleukin-6: lipolytic, anti-inflammatory and immune regulatory effects. Pflugers Arch. 2003; 446: 9-16.
61. Grounds M.D. and Torrisi J. Anti-TNF-a (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J. 2004; 18: 676-82.
62. Kuru S., Inukai A., Kato T., Liang Y., Kimura S., and Sobue G. Expression of tumor necrosis factor-a in regenerating muscle fibers in inflammatory and noninflammatory myopathies. Acta. Neuropathol. (Berl.) 2003; 105: 217-24.
63. Hansen L., Gaster M., Oakeley E.J., Brusgaard K., Damsgaard Nielsen E.M., Beck-Nielsen H., Pedersen O., and Hemmings B.A. Expression profiling of insulin action in human myotubes: induction of inflammatory and pro-angiogenic pathways in relationship with glycogen synthesis and type 2 diabetes. Biochem. Biophys. Res. Commun. 2004; 323: 685-95.
64. Alon T., Friedman J.M., and Socci N.D. Cytokine-induced patterns of gene expression in skeletal muscle tissue. J. Biol. Chem. 2003; 278: 32324-34.
65. Faldt J., Wernstedt L., Fitzgerald S.M., Wallenius K., Bergstrom G., and Jansson J.O. Reduced exercise endurance in interleukin-6-deficient mice. Endocrinology 2004; 145: 2680-6.
66. Llovera M., Garcia-Martinez C., Lopez-Soriano J., Carbo N., Agell N, Lopez-Soriano F.J., and Argiles J.M. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol. Cell. Endocrinol. 1998; 142: 183-9.
67. Hengstman G.J., van den Hoogen F.H., Barrera P., Netea M.G., Pieterse A., van de Putte L.B., and van Engelen B.G. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-a: preliminary observations. Eur. Neurol. 2003; 50: 10-5.
68. Madihally S.V., Toner M., Yarmush M.L., and Mitchell R.N. Interferon y modulates trauma-induced muscle wasting and immune dysfunction. Ann. Surg. 2002; 236: 649-57.
69. Riechman S.E., Balasekaran G., Roth S.M., and Ferrell R.E. Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses. J. Appl. Physiol. 2004; 97: 2214-9.
70. Fernandez-Celemin L., Pasko N., Blomart V., and Thissen J.P. Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-a. Am. J. Physiol. Endocrinol. Metab. 2002; 283: E1279-90.
71. Vassilakopoulos T., Divangahi M., Rallis G., Kishta O., Petrof B., Comtois A., and Hussain S.N. Differential cytokine gene expression in the diaphragm in response to strenuous resistive breathing. Am. J. Respir. Crit. Care Med. 2004; 170: 154-61.
72. Nieman D.C., Davis J.M., Henson D.A., Walberg-Rankin J., Shute M., Dumke C.L., Utter A.C., Vinci D.M., Carson J.A., Brown A., Lee W.J., McAnulty S.R., and McAnulty L.S. Carbohydrate ingestion influences skeletal muscle cytokine mRNA and plasma cytokine levels after a 3-h run. J. Appl. Physiol.2003; 94: 1917-25.
73. Horsley V., Jansen K.M., Mills S.T., and Pavlath G.K. Il-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 2003; 113: 483-94.
74. Figueras M., Busquets S., Carbo N., Barreiro E., Almendro V., Argiles J.M., and Lopez-Soriano F.J. Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBSLett. 2004; 569: 201-6.
75. Carbo N., Lopez-Soriano J., Costelli P., Busquets S., Alvarez B, Baccino F.M., QuinnL.S., Lopez-Soriano F.J., andArgiles J.M. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br. J. Cancer 2000; 83: 526-31.
76. Furmanczyk P.S. and Quinn L.S. Interleukin-15 increases myosin accretion in human skeletal myogenic cultures. Cell. Biol. Int. 2003; 27: 845-51